Long-term use of Ibrutinib can inhibit CSK from phosphorylating the carboxyl terminal of Src family kinases (SFK), which leads to the enhancement of SFK activity, atrial fibrosis, and activation of inflammatory reactions, thus increasing the susceptibility to AF (Figure 2). The gene discussed is CSK; the disease is atrial fibrillation.